Global Fatty Liver Day 2024 was a huge success!
Check out our “At a Glance” report for highlights. Stay tuned for the full Global Fatty Liver Day 2024 report.
⬇️NEW Provider Education Resources Available ⬇️
Endocrinologists and PCPs: The Frontline Defense Against Cirrhosis in Patients with Type 2 Diabetes
This series of bite-sized episodes will provide important information on MASLD and MASH in patients with type 2 diabetes. Drs. Naim Alkhouri and Robert Eckel and physician assistant Tessa Janovsky discuss best practices for screening, diagnosis, treatment, and management of MASH/MASLD.
Build Your Own Case Study | Redefining MASLD/MASH Care: Personalized Strategies for Assessment, Diagnosis and Management
Health Care Providers in the endocrinology specialty setting are challenged to be knowledgeable of the pathophysiology of MASLD and MASH and its associated risk factors, as well as feel confident around how and when to order noninvasive diagnostic tests to prevent the emergence of more severe complications and stay on top of current guidelines and emerging treatment options.
Explore this interactive learning format, Build Your Own Case Study. By participating in this activity, you will gain valuable insights into effectively addressing MASLD/MASH for improved patient health.
The NASH Patient Assistance Fund: Apply Today!
The Assistance Fund is currently accepting applications for their new NASH Financial Assistance Program! The program provides financial assistance for prescription drug assistance (copays, deductibles, and coinsurance) on FDA-approved treatment, health insurance premiums, therapy administration costs, and treatment-related ground travel costs. Eligibility information is available on the program website (linked above) and applications can be submitted here!
By Letting Patients Lead, We Can Advance Medicine
Trauma-informed, patient-led consultations to build trust and enhance medical care are important to clinical care for liver health, Dr. Julia Wattacheril, Director of the MASLD Program at Columbia’s Center for Liver Disease and Transplantation, has emphasized. She challenges the conventional link between NAFLD and obesity and advocates for a more nuanced understanding that considers individual experiences, trauma, and diverse demographics.
Survodutide Shows Promise in Treating Fatty Liver Disease
A new trial led by Dr. Arun Sanyal, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at the Virginia Commonwealth University School of Medicine, suggests that survodutide, an experimental dual-agonist drug, significantly improved markers of fatty liver disease in up to 83% of patients. The study highlights survodutide’s promise as a future treatment option for nonalcoholic fatty liver disease, a condition affecting about 1 in 4 people globally.
Link Found Between Malnutrition and Liver Health in Hospitalized Patients
Even as overnutrition has been closely linked with fatty liver disease, malnutrition can also have a harmful effect on the liver. A study of 247 hospitalized patients revealed that severe liver fat accumulation was associated with higher in-hospital mortality and longer stays. The study also identified the CONUT score (a blood-based measure of malnutrition) as a useful tool for assessing nutrition status in hospital settings, showing that a high score independently predicted a higher risk for infections.
Upcoming Events
- Join us at our next Fatty Liver Disease Council Meeting on Thursday, July 18, 2024. For more info, visit globalliver.org/fatty-liver-disease-council or email fattyliverdisease@globalliver.org.
- September 13-16, 2024: GLI’s Advanced Advocacy Academy (A3)
